Company halts clinical studies and any further molecule development.
RG6174 (GDC-0334) is a drug that as being developed by Genentech for the treatment of inflammatory diseases. The candidate had reached the phase 1 clinical study stage late in 2017, but the company was unable to enroll a sufficient number of patients and after extending the targeted closing date, the trial was canceled. Roche has since terminated molecule development.
The company never disclosed much information about the program and has not discussed its mechanism of action nor any specific targeted indications. The termination was disclosed as part of a quarterly update.
